Half of strictly immune-tolerant hepatitis B patients became immune-active within five years

Design

International multicentre cohort study (RADICAL consortium)

Population

951 patients with strictly defined immune-tolerant chronic hepatitis B (median age 33)

Primary outcome

Transition to immune-active disease, significant fibrosis and HCC

Effect

Immune-active: 51% at 5 y, 72% at 15 y; ALT >30 U/L sHR 3.13; HCC 1.1% at 15 y

The RADICAL consortium followed 951 patients with chronic hepatitis B strictly defined as immune tolerant for their first year: HBeAg-positive, ALT at or below 40 U/L, HBV DNA above 7 log IU/mL and fibrosis F0 to F1. Median age was 33, and median follow-up 13 years.

Transition to immune-active disease (ALT 50 U/L or more) occurred in 51% within 5 years, 67% within 10 and 72% within 15. High-normal ALT at baseline raised the risk (subdistribution HR 1.74 for 20 to 30 U/L and 3.13 for above 30 U/L). Progression to significant fibrosis (6.3%) and HCC (1.1%) at 15 years was uncommon.

The immune-tolerant phase is less stable than often assumed. Most patients will need treatment eventually, and those with ALT in the upper-normal range need closer watching. For India, where HBV is common and many patients are young and HBeAg-positive, this supports regular follow-up rather than discharge.

• Do not discharge immune-tolerant hepatitis B patients; most move to immune-active disease within 5 years.
• Check ALT and HBV DNA at least every 6 months, more often if ALT is 30 U/L or above.
• Use the sex-specific ALT upper limits in hepatitis B guidelines, which are lower than most laboratory ranges.
• Screen household and sexual contacts, and vaccinate those who are non-immune.
• Family history of HCC or cirrhosis may justify treatment even in immune-tolerant phase.

Why it matters

It weakens the case for leaving immune-tolerant patients untreated and unwatched.

Don't overread it

This is observational natural history; it does not show that treating immune-tolerant patients improves long-term outcomes.

The statistics, in plain English

A subdistribution hazard ratio of 3.13 means patients with ALT above 30 U/L had about three times the rate of becoming immune-active, accounting for other events. The low HCC rate (1.1% at 15 years) reflects a young cohort and may not apply to older patients.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.